FLT3 and acute myeloid leukemia: In one study, mutant length and number had no significant impact on outcome,7 whereas others reported that patients with shorter ITDs have a lower relapse rate and more favorable outcome than those with longer ITDs.11, 12, 13 It is therefore necessary to clarify the significance of those indicators to determine the ideal treatment modality in AML with FLT3-ITD.